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SIMULTANEOUS 
MANIPULATION OF THE 
NITRIC OXIDE AND 
PROSTANOID PATHWAYS 
REDUCES MYOCARDIAL 
REPERFUSION INJURY 
The effects of aspirin and L-arginine (biological precursor of nitric oxide) on 
the production of hydroxyl radicals, cyclic guanosine monophosphate levels, 
vascular tone, and the recovery of the ischemic myocardium were investigated 
in isolated rat hearts ubjected to ischemia nd reperfusion. After 30 minutes 
of perfusion, hearts were arrested with St. Thomas' Hospital cardioplegic 
solution, global ischemia was induced at 37 ° C for 45 minutes, and the hearts 
were then reperfused at 37 ° C for 30 minutes. The percent change in recovery 
of pulse pressure and maximal change of this pressure with time were better in 
the group perfused with Krebs-Henseleit solution containing aspirin plus 
L-arginine (17% -- 23%, p = 0.001, and 10% -.+ 25%, p = 0.002, respectively) 
compared with these values in the control group perfused with Krebs-Henseleit 
solution alone (-7% _ 14% and -11% -.+ 16%, respectively). Coronary 
vascular esistance before and after ischemia were lower in the aspirin plus 
L-arginine group (0.19 --.+ 0.03 dynes, sec/cm s, p = 0.001, and 0.23 _ 0.04 
dynes, sec/cm s, p = 0.01, respectively) compared with those of the control 
group (0.24 - 0.02 and 0.28 - 0.07 dynes, sec/cm s, respectively). Cyclic 
guanosine monophosphate levels increased from 22.5 - 6 pmol/100 mg of 
tissue in the control group to 37.1 -+ 8.9 pmol/100 mg (p = 0.002) in the aspirin 
plus L-arginine group. Adding Nco-nitro-L-arginine methyl ester to the perfu- 
sion medium caused a deterioration i pulse pressure and maximal change of 
this pressure with time, a decrease in cyclic guanosine monophosphate, and a 
rise in coronary vascular resistance. The addition of L-arginine to the solution 
in the Krebs-Henseleit solution plus aspirin group increased the production of 
hydroxyl radicals from 0.32 - 0.18 nmol/gm per 3 minutes to 0.75 --- 0.33 
nmol/gm per 3 minutes (p = 0.03). Despite the association of nitric oxide with 
increased hydroxyl radical production, it appears that nitric oxide has an 
overall beneficial effect on the recovery of the ischemic myocardium. The 
synergism between aspirin and arginine may be caused in part by the 
scavenging ofhydroxyl radicals. Alternatively, by inhibiting the prostaglandin 
pathway, aspirin may reduce the generation of superoxide anion, a free radical 
that inactivates nitric oxide. The prolonged half-life of nitric oxide may explain 
the increased levels of cyclic guanosine monophosphate s en in the group 
perfused with Krebs-Henseleit solution plus aspirin plus L-arginine. Aspirin 
and L-arginine, both readily available, may be useful adjuncts to clinical 
cardioplegia strategy. (J THORAC CAPd)IOVASC SURG 1995;110:1054-62) 
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A growing number of studies have implicated 
oxygen-derived free radicals as important in isch- 
emia-induced myocardial reperfusion injury)' 2 Pro- 
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duced at reperfusion by a variety of mechanisms, 3-8 
oxygen free radicals depress myocardial function 
and cause lipid peroxidation of membranes and 
scission of deoxyribonucleic acid and polypeptide 
chains both in vivo and in vitro. 9 Additionally, they 
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have been implicated as contributors to the phe- 
nomenon of stunned myocardium, z 
Since the discovery of endogenous nitric oxide by 
Furchgott and Zawadski 1° in 1980, there have been 
conflicting reports as to the effect of nitric oxide on 
the recovery of ischemic myocardium. Some animal 
studies have shown a beneficial effect of nitric oxide 
through its regulation of coronary vascular toneJ 1' 12 
However, other investigators have recently sug- 
gested that nitric oxide (NO) may cause an adverse 
effect on myocardial recovery by increasing the 
production of hydroxyl radicals (OH) via the follow- 
ing pathway 13' 14: 
.NO + .O2- ~ ONOO- 
ONOO- + H + --~ ONOOH 
,~.OH + .NO 2 (20% to 30% yield) 
ONOOH 
NNO3- + H + (remainder) 
Direct cellular, tissue, or whole organ is measure- 
ments of hydroxyl radical production by nitric oxide 
degeneration have heretofore not been made. De- 
tection of oxygen free radicals is complicated by 
their highly reactive and transient nature. Recently, 
however, acetylsalicylic acid (aspirin) has been used 
as a "trap molecule" to detect and quantify hydroxyl 
radical production in biochemical reactions. 16 Given 
this function, we thought that aspirin might there- 
fore also serve as a scavenger of hydroxyl radical in 
biologic systems. These complementary properties 
of aspirin suggest that it might be used to help 
uncover the effect that nitric oxide has on myocar- 
dial recovery after ischemia. 
In the present study, we designed a whole-organ 
(isolated rat heart) model that allows us to investi- 
gate the following hypotheses: (1) exogenously ad- 
ministered nitric oxide increases the production of 
hydroxyl radicals in the ischemic myocardium, (2) 
despite this increased production of hydroxyl, nitric 
oxide does not have a significantly deleterious effect 
during reperfusion after ischemia, and (3) aspirin 
acts synergistically with nitric oxide to substantially 
improve myocardial recovery after ischemia. 
Material and methods 
Heart preparation. Male Sprague-Dawley rats (250 to 
300 gin) were given anticoagulation treatment by injection 
of 1000 USP units of heparin sodium per kilogram and 
anesthetized by intraperitoneal injection of a 30 mg/kg 
dose of pentobarbital. The hearts were rapidly excised and 
immersed in ice-cold perfusion buffer. Within 1 minute of 
Tahle I 
Groups, No. of hearts 
KH (Control) 18 
KH + ASA (1 mmol/L) 26 
KH + ARG (3 mmol/L) 24 
KH + ASA + ARG 24 
KH + L-NAME (100 p~mol/L) 8 
KH, Kl'ebs-Henseleit solution; ASA, aspirin; ARG, L-arginine. 
excision, the hearts were perfused in a retrograde fashion 
through the aorta according to the Langendorff method 
with a modified Krebs-Henseleit solution (composition of 
the Krebs-Henseleit solution in millimoles per liter: NaC1 
118.5, NaHCO 3 25.0, KC1 4.9, KHzPO 4 1.2, MgSO4 1.2, 
CaC12, 1.4, and glucose 11.1; pH 7.4). All solutions, 
including the cardioplegic solution were prepared fresh 
daily, gassed with 95% Oz plus 5% CO2, warmed to 37 ° C, 
and passed through a0.45 ~m filter before use. Each heart 
beat spontaneously and none was paced. 
All animals in this study were treated humanely in 
accordance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
1985), as well as the requirements of the Research Animal 
Review Committee of the Children's Hospital Oakland 
Research Institute, which reviewed and approved the 
experimental protocol. 
Experimental protocol. L-Arginine (biologic precursor 
of nitric oxide) was used to stimulate the production of 
nitric oxide in the myocardium. Nw-nitro-L-arginine 
methyl ester (L-NAME) was used to inhibit basal nitric 
oxide production. Aspirin served as a scavenger and a trap 
molecule for hydroxyl radical production. By design, the 
experimental protocol was set to simulate conditions 
encountered in a typical cardiac operation. Therefore our 
hearts were subjected to conditions that inflicted on them 
a minimal to moderate amount of damage. Hearts were 
perfused at 37 ° C for a 35-minute period at a pressure of 
about 70 mm Hg with one of the five perfusion media 
listed in Table I. The perfusion was then stopped, and St. 
Thomas' Hospital cardioplegic solution (composition of 
St. Thomas' Hospital solution in millimoles per liter: NaC1 
110.0, NaHCO 3 10.0, KC1 16.0, CaC12 1.2, MgC12 16.0, and 
glucose 11.1; pH 7.8) was infused into the aortic root at 45 
mm Hg for 1 minute. The hearts were kept arrested for 45 
minutes, a period simulating the typical duration of car- 
dioplegic arrest during heart operations. During this time 
the hearts were immersed in St. Thomas' Hospital solu- 
tion (at 37 ° C) to prevent oxidative reactions from taking 
place on the surface of the hearts. Rat hearts are known to 
recover well from a 45-minute period of hypothermic (5° 
to 15 ° C) ischemia. To inflict measurable damage during 
the ischemic period, therefore, the hearts were main- 
tained at 37 ° C. This was followed by another 35 minutes 
of aerobic reperfusion. 
Heart rate expressed as beats per minute, left ventric- 
ular pulse pressure (P) expressed in millimeters of mer- 
1056 Wanna et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
October 1995 
Excision and loading 
of the heart 
l 15 min. recording 
45 min. of cardioplegic arrest 
T 20 min. equilibrium 
1 min. infusion 
of St. Thomas 
solution 
 /SY/A 
Fig. 1. Bar displays progression of experiment as function of time. 
cury, and the maximal change of this pulse pressure with 
time (dP/dt) expressed in units of millimeters of mercury 
per second were recorded with use of a compliant fluid- 
filled balloon catheter that was inserted into the left 
ventricle by way of the left atrial appendage through the 
mitral valve. The catheter was connected to a pressure 
transducer. Data were sampled at a rate of 200 Hz by a 
software program (LabTech, Inc., Wilmington, Mass.) and 
differentiated in real time. Recordings were made contin- 
uously for 15 minutes after a 20-minute quilibrium time. 
The timing of the events is shown in Fig. 1. 
A transducer placed in the aortic cannula allowed a 
continuous recording of aortic root pressure (ARP). The 
coronary flow (CF) was measured by timed collection of 
coronary effluent at 5-minute intervals during the experi- 
ment. Coronary vascular esistance (CVR) was then cal- 
culated as CVR = ARP/CF and expressed in dynes times 
second per centimeter to the fifth power. 
Mechanical function quantities were expressed as per- 
cent fractional change (%A), whereby %A of a variable 
X = ([value of X after ischemia minus value of X before 
ischemia]/value of X before ischemia) x 100. 
Measurement of hydroxyl radical. Aspirin is known to 
react with hydroxyl radical to form catechol and 2,3- and 
2,5-dihydroxybenzoic acid (DHBA) as shown in Fig. 2. 
These reaction products were extracted from the coronary 
sinus effluent and quantified with the use of high-perfor- 
mance liquid chromatography (HPLC) as described by 
Floyd and Wong 16 and modified by Onodera and 
Ashraf. 17 
To determine the appropriate sampling interval, we ran 
the following experiment. We assayed the coronary sinus 
effluent every 5 minutes before ischemia and every 30 
seconds after ischemia. We found the preischemic con- 
centration of hydroxyl radical to be less than our detect- 
able limit of 10 -12 mol/L and that, after ischemia, the 
hydroxyl radical concentration decreased again to less 
than our detectable limit after 3 minutes of reperfusion. 
Therefore we decided to determine the total number of 
hydroxyl radical molecules that appeared in the coronary 
sinus effluent in the first 3 minutes of reperfusion per 
gram of tissue. 
In brief, 2 ml of the total coronary sinus effluent volume 
collected in the first 3 minutes after reperfusion was 
treated with 50 ~1 of 100 #zmol/L 2,4-DHBA (an internal 
standard) and 100 ~1 of 1N HCI. The solution was then 
extracted with 6 ml of HPLC-grade diethyl ether, centri- 
fuged at room temperature. The extraction and centrifu- 
gation steps were repeated three times. The diethyl ether 
layers were combined and evaporated to dryness in a 
water bath at 45 ° C. The residue was then dissolved in 60 
/zl of 1N HC1 and 40 #zl of mobile phase described later. 
Forty microliters of this solution was injected into the 
HPLC apparatus. Separation was made on a Bio-sil C18 
HL90-5S column, 250 × 4.6, from Bio-Rad Laboratories 
(Richmond, Calif.), with an attached precolumn. The 
effluent was 80% 0.03 mol/L citric acid, 0.03 mol/L acetic 
acid buffer, pH 3.6, and 20% methanol at a flow rate of 1.0 
ml/min. The ultraviolet detection was set at a wavelength 
of 315 nm. 
Cyclic guanosine monophosphate assay. The con- 
centration of cyclic guanosine monophosphate (cGMP) 
was assayed as an indicator of nitric oxide activation 
of guanylate cyclase. 18"19 Frozen heart samples were 
weighted and homogenized in cold 6% (weight/volume) 
trichloroacetic acid at 2 ° to 8 ° C to give a 10% (weight/ 
volume) homogenate. After centrifugation at2000 g for 15 
minutes at 4 ° C, the supernatant was collected and washed 
four times with four volumes of water-saturated diethyl 
ether. The aqueous extract remaining was then lyophi- 
lized, cGMP contents of the extracted supernatant were 
determined with the use of Amersham enzyme immuno- 
assay kits (Arlington Heights, ILL). Concentration of 
cGMP was expressed as picomoles per 100 mg of tissue. 
Chemicals. All chemicals were obtained from Sigma 
Chemical Co., St. Louis, Missouri, or VWR, Boston, 
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COOH @ H(11%) 
CATECHOL 
COOH CO 2 
+ .OH 
SALICYLIC ACID COOH 
° ~H' ~ (40%) 
2,5-DIHYDROXYBENZOATE 
COOH 
°~ L~°l ~oH(4 */.) 
2,3-DIHYDROXYBENZOATE 
Fig. 2. Measurable reaction products of salicylic acid with hydroxyl radical (OH). 
Massachusetts. Diethyl ether and methanol were of HPLC 
grade. Distilled deionized water was used throughout. 
Statistical analysis. All data are expressed as mean 
plus or minus the standard eviation. Statistical analysis 
was done comparing results in control versus intervention 
groups by analysis of variance followed by the Student's t 
test with the Bonferroni correction. The p value is listed 
for each measurement. 
Results 
Mechanical function. Hearts in the control 
group, perfused with Krebs-Henseleit solution with- 
out any additional agent, had values of %A (P) and 
%A (dP/dt) of -7  ± 14 and -11 ± 16, respectively. 
The addition of aspirin or L-arginine alone to the 
perfusion medium improved the values of %A (P) 
and %A (dP/dt) modestly but not to statistically 
significant levels. When the perfusion medium was 
changed to Krebs-Henseleit solution plus aspirin 
plus L-arginine, %A (P) and %A (dP/dt) values 
improved significantly to + 17 _+ 23 (p = 0.001) and 
+ 10 ± 25 (p = 0.002), respectively, as shown in Fig. 
3. Conversely, the addition of L-NAME to the 
Krebs-Henseleit solution caused a significant de- 
crease in both P and dP/dt values before and after 
ischemia when compared with values in control 
hearts. 
To account for the possible dependence of P and 
dP/dt on heart rate, we normalized these indices by 
dividing them by the heart rate and reanalyzed the 
groups. This new variable behaved very similarly 
to the unnormalized indices of systolic function, 
whereby the group perfused with aspirin plus L- 
arginine had statistically significant improved in- 
dices as compared with those in control hearts. 
Coronary vascular resistance. Ischemia caused 
an increase in the resistance in all groups studied 
(Fig. 4). Control values of coronary vascular esis- 
tance before and after-ischemia were 0.24 ± 0.02 
and 0.28 _+ 0.07 dynes, sec/cm 5, respectively. In the 
groups perfused with L-arginine or aspirin alone 
coronary vascular resistance was modestly lower 
than that in control hearts but not to statistically 
significant levels. In the group perfused with Krebs- 
Henseleit solution plus aspirin plus L-arginine, cor- 
onary vascular resistance values before and after 
ischemia were 0.19 _ 0.03 (p = 0.001) and 0.23 +- 
0.04 dynes, sec/cm 5 (p = 0.01), respectively (Fig. 4). 
As expected, by decreasing basal nitric oxide con- 
centration, L-NAME caused a dramatic increase in 
both preischemic and postischemic coronary vascu- 
lar resistance to 0.39 _ 0.03 (p = 0.3 x 10 -5) and 
0.42 __- 0.07 dynes, sec/cm 5 (p = 0.002), respectively, 
when compared with values in control hearts (Fig. 4). 
Hydroxyl radical production. No DHBA was de- 
tected in the effluent in the preischemic period. The 
concentration of DHBA was highest immediately 
after the start of reperfusion. Subsequently, DHBA 
concentration decreased to below detectable l vels 
within 3 minutes of reperfusion. The postischemic 
concentration of DHBA was almost double in the 
group subjected to aspirin plus L-arginine (0.75 ± 
0.33 nmol/gm per 3 minutes, p = 0.03) compared 
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Fig. 3. Effect of four different perfusion media on per- 
cent recovery of P and dP/dt. Each column represents 
mean and bars indicate standard eviation. KH, Krebs- 
Henseleit solution; ASA, aspirin; ARG, L-arginine; *p < 
0.001; **p < 0.002 compared with control (group receiv- 
ing only Krebs-Henseleit solution). 
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Fig. 4. Effect of five different perfusion media on coro- 
nary vascular resistance (CFR) both before (pre-) and 
after (post-) ischemia. KH, Krebs-Henseleit solution;ASA, 
aspirin; ARG, L-arginine; *p < 0.001; **p < 0.01; tp < 
0.3 × 10-5; tip < 0.002 (groups compared with control 
group receiving Krebs-Henseleit solution only). 
with that in the group subjected to aspirin alone 
(0.32 _+ 0.18 nmol/gm per 3 minutes) (Fig. 5). (Note 
that, in the present study design, DHBA could not, 
by definition, be detected in groups not perfused 
with aspirin.) 
cGMP production, cGMP concentration i the 
control group was 22.5 _+ 6 pmol/100 rag. cGMP 
levels were significantly increased in the hearts 
perfused with aspirin plus L-arginine (37.14 ___ 8.9 
pmol/100 rag, p = 0.002). Conversely, the addition 
of L-NAME resulted in a significant decrease in 
cGMP levels when compared with those in control 
hearts (11.75 _ 4.3 pmol/100 mg, p = 0.006). Hearts 
perfused with aspirin or L-arginine alone gave 
cGMP levels similar to control evels (Fig. 6). 
Discussion 
Nitric oxide is a labile molecule synthesized from 
the amino acid L-arginine via the enzyme nitric 
oxide synthase and is equivalent o endothelium- 
derived relaxing factor), a° Once released, nitric ox- 
ide is believed to carry on intracellular messenger 
functions leading to the activation of guanylate 
cyclase by a heme-dependent mechanism. Activated 
guanylate cyclase causes an increase in cGMP con- 
centration.18, w Increased levels of cGMP lead, in 
turn, to vasorelaxation and better tissue perfu- 
sionJl, 12 Nitric oxide is continuously released from 
the endothelium al and appears to play other impor- 
tant roles, such as mediation of inflammation 22 and 
thrombosis a3and inhibition of platelet adhesion and 
aggregation, a4 In addition to its vasodilatory prop- 
erties, nitric oxide has been implicated as an inde- 
pendent source for the production of the deleterious 
hydroxyl radicals in the ischemic myocardiumJ 3' 14 
Hydroxyl is a short-lived radical, produced in the 
myocardium during different pathologic onditions, 
including ischemia/reperfusion. Although other rad- 
icals are also born in the ischemia/reperfusion pro- 
cess (notably superoxide anion and hydrogen per- 
oxide) these are not considered to be as injurious to 
the myocardium. For example, superoxide anion 
reacts slowly under physiologic onditions and hy- 
drogen peroxide is a relatively weak oxidant. 25' 26 
The Journal of Thoracic and 
Cardiovascular  Surgery 
Volume 110, Number  4, Part 1 
Wanna et al. 1059 
1.25  
0.75 
~ 0.5 
0.25 
[] OH 
T 
Iiii!iii  iiiil 
I 
0 
0 
II 
, . , . , . , , , , , , , . , , , , , , , , , , , , , , . , , ,  
. ° . . . . . . . . , . . . , . , . , . , . . . , . . . . . . . .  
. . . . . . . . . , , . , , . . , . , . , . . . , . . . • . . . ,  
. . . . . . . . . , . . . . . . , . , . , • . . , .o . . . , . .  
. . . . . • . . . . , . , ° . . . . , . , . , . , . . . . . o . .  . . . . . . . , . • . . . . . . . . . . . . . . . . • . . . . . .  
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  
. - . - . - , - . . . . . - . . . . . . . . . . . . . . . . . . .  
. - . - . - . . , . . . . - . . . . . . . . . . . . . . . . . . .  
. . . - . - . - . . . - . - , - . . . - . . . - . . . . , . , . , ,  
. . , - . . . . , . , . , . . - . - . . . , . , . - . . . . . . . ,  
. . . - . - . . . . . , . . . - . - . . . . . . . - . . . - . . . ,  
, , . - , , . , , ,  , . , . - , - , , , , , , , , , . , , , , , ,  
. . . . . . . . . . . . . . . . . , . . . . . . . . - . , . . . ,  
, . , . . . , . , . . . . . . . . - . . . . . . . . . . . , . . .  
. , . . . . . . . , . . . . . . , , . . . . , . . . . . . . . . .  
. . . . . . . . , . . . . . . . . . . . , . . . . . . . . . .  
. . . . . . . . , . . ,  . , . . . . . . . . . . . . . , . .  
. , . . . . . . . . , . . . . , . . . . . . . . . . , . . . . . .  
. , , . . . , . , . . . . . . . . . . . . . . . . . . . . . .  
. .  , . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
, ,  , , .  , , , , , , , , , . , , ,  , , ,  , . , . , . , .  
. . . . . . . ,  . . . . . . . . . . . . . . . . . , . . . , . .  
. . . . . . . . . . . . . . . . . . . . . . . . . , . . . . . , .  
. . . . . . . ,  . , . , . . . . , . . . , . . . . . . . . . .  
. . . . . . . . . , . . . . . , . . , . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . . . o . , . . . . . , . , . .  . . . .  . . . . . . . .  . . . . .  
I 
÷ 
r~ 
+ 
Fig. 5. Effect of adding L-arginine (ARG) to perfusion 
medium on production of hydroxyl radicals (OH) KH, 
Krebs-Henseleit solution; ASA, aspirin. 
Hydroxyl radical, on the other hand, is highly reac- 
tive and has been shown to cause membrane dam- 
age, lipid peroxidation, and deoxyribonucleic a id 
breakage. 9 Studies have demonstrated that by pre- 
venting the formation of hydroxyl radicals with the 
use of allopurinol, an inhibitor of xanthine oxi- 
dase, 27 or deferoxamine, an inhibitor of iron-cata- 
lyzed hydroxyl radical generation, 28" 29 one can im- 
prove myocardial recovery after ischemia. Because 
of its short half-life, the hydroxyl radical is extremely 
difficult to measure in biologic systems. 
In an attempt o investigate whether nitric oxide 
represents a significant source of these hydroxyl 
radicals in the myocardium, we used a novel and 
specific chromatographic technique (HPLC) devel- 
oped by Floyd and Wong 16 and modified by On- 
odera and Ashraf, 17 which permitted us to compare 
the quantities of hydroxyl radical released into the 
coronary effluent in the presence or absence of 
L-arginine. Our study has provided the first direct 
measurement of increased hydroxyl radical produc- 
tion, in an isolated perfused heart, as a result of 
enhancing nitric oxide production in the myocar- 
dium with the use of L-arginine. These findings are 
complementary to the work of Beckman and Free- 
man, 13 who found that nitric oxide leads to in- 
creased production of hydroxyl radical in chemical 
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Fig. 6. Tissue levels ofcGMP in hearts perfused with five 
different media. Note significant differences b tween KH 
+ ASA + ARG (Krebs-Henseleit plus aspirin plus L- 
arginine) and KH + L-NAME (Krebs-Henseleit solution 
plus L-NAME) groups, respectively. Interestingly, neither 
aspirin nor L-arginine alone had much effect on cGMP 
levels. 
reactions. Hydroxyl radical release peaked in the 
first 3 minutes after reperfusion. This time course 
has been reported in other studies that investigated 
other radical species and used other techniques. 3°' 31 
By restricting our peffusion media in this study to 
crystalloid, we eliminated the contribution of poly- 
morphonuclear leukocytes, which can produce a 
variety of toxic species such as NH2C1, HOC1, and 
hydroxyl radical. This was done to isolate the con- 
tribution of the endothelial cells and myocytes to 
oxidative damage. 
The current experiment demonstrates a modest 
improvement of P and dP/dt and a slight decrease in 
coronary vascular esistance in an isolated rat heart 
perfused with L-arginine. One possible interpreta- 
tion of these findings is that nitric oxide does not 
affect myocardial function. We tested this hypothe- 
sis by perfusing hearts with a nitric oxide inhibitor, 
L-NAME. We noted a significant increase in coro- 
nary vascular resistance and a dramatic decrease in 
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Fig. 7. Schematic representation shows generation of superoxide anion (.02-) via cyclooxygenase pathway 
and its effect on nitric oxide (NO). Note how nitric oxide in endothelial cells influences concentration of
cGMP in smooth muscle cells. PGG2, Prostaglandin G2; PGH2, prostaglandin H2; TXA2, thromboxane A2; 
PGI2, prostacyclin; ?CAD, nicotinamide-adenine dinucleotide; cAMP, cyclic adenosine monophosphate; 
ASA, aspirin. 
mechanical function, thus implying that the pres- 
ence of nitric oxide, at least at a baseline level, is 
important for the maintenance of myocardial func- 
tion. This finding is also supported by Amrani and 
Yacoub, 32 who found that inhibition of the release 
of basal nitric oxide was associated with a significant 
decrease in cardiac output and that L-NAME itself 
was not toxic to myocardial tissue. 
Another possible interpretation of our results is 
that the addition of exogenous nitric oxide to the 
perfusate results in both deleterious and beneficial 
effects in roughly comparable proportions. Thus the 
harmful effect of the increase in production of 
hydroxyl radicals might be roughly balanced by the 
salutory effects of the decrease in coronary vascular 
resistance and presumed improvement in tissue 
perfusion. To test this supposition, we studied myo- 
cardial recovery in the presence of both exogenous 
nitric oxide and a known free radical scavenger, 
aspirin. Both substances added simultaneously to 
the perfusate resulted in a significant increase in 
postischemic recovery of myocardial mechanical 
function and a decrease in coronary vascular esis- 
tance. By scavenging some of the hydroxyl radicals, 
aspirin may have unmasked the salutory effect of 
nitric oxide on vascular tone and allowed better 
tissue perfusion and, eventually, better myocardial 
recovery after ischemia. The importance of the 
presence of nitric oxide in this synergism is further 
demonstrated bythe fact that improvement in func- 
tion was only modest when aspirin alone was added 
to the perfusate, that is, hydroxyl radicals were 
scavenged without the additional benefit of en- 
hanced nitric oxide. 
Although the direct free radical scavenging activ- 
ity of aspirin may well have played a significant role 
in the synergism displayed in this study between 
aspirin and L-arginine, there is another possible 
mechanism by which aspirin might have acted. By 
inhibiting the cyclooxygenase pathway, aspirin may 
affect tissue levels of nitric oxide. Cyclooxygenase 
catalyzes the oxygenation of arachidonic acid to 
prostaglandin G 2 and hydroperoxidase converts this 
to prostaglandin H 2. The peroxidase-catalyzed con- 
version of prostaglandin G2 to prostaglandin H2 
yields superoxide anion, 33' 34 a well-known scaven- 
ger of nitric oxide. 35' 36 It is, therefore, possible that 
aspirin, by inhibiting the cyclooxygenase pathway, 
reduces tissue production of .O2-, leading to an 
increased half-life of nitric oxide (Fig. 7). The 
increase half-life of nitric oxide will subsequently 
increase cGMP production by activating uanylate 
cyclase.lS, 19 Indeed, we found augmented levels of 
cGMP in the group perfused with aspirin plus 
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L-arginine, whereas L-NAME, by inhibiting basal 
nitric oxide production, significantly decreased the 
levels of this cyclic nucleotide in tissue. Thus the 
cGMP data lend support to the proposed mecha- 
nism of interaction between the cyclooxygenase and 
nitric oxide pathways. This mechanism is further 
supported by the work of Johnson and Lefer, 37 who 
found that nitric oxide acted synergistically with a 
scavenger of superoxide anion, superoxide dis- 
mutase, to confer significant protection on the myo- 
cardium subjected to ischemia and reperfusion in- 
jury. 
In this study, we have focused mainly on the 
hydroxyl radical as the instigator in ischemia/reper- 
fusion injury. However, it is clear from recent stud- 
ies that other reactive oxidant species, such as 
singlet oxygen (102) , produced uring ischemia nd 
reperfusion may be as harmful as hydroxyl. 10 2 can 
be generated from the reaction of nitric oxide with 
H202 .3s 10 2 has been shown to cause amino acid 
photooxidation, damage cardiac sarcoplasmic retic- 
ulum function, 39 and cause arrythmias. 4° The rela- 
tive role that .OH and 10 2 play in ischemic/reper- 
fusion injury remains unclear. 
Yet another limitation of this study is the addition 
of nitric oxide and aspirin to the perfusion in the 
preischemic and the reperfusion intervals. This de- 
sign does not permit one to tell specifically what, if 
any, preconditioning effect hese agents might have 
had to explain the postischemic improvement in 
recovery. Additionally, the clinical use of aspirin 
might be limited by its tendency to increase bleeding 
because of platelet dysfunction. This problem could 
be obviated, however, by isolating the coronary 
perfusion circuit from the systemic ircuit during 
early reperfusion, a method that is already used 
often in the clinical setting. 
In conclusion, we have demonstrated that nitric 
oxide leads to an increased generation of hydroxyl 
radicals immediately after the start of reperfusion i  
the isolated perfused rat heart model. Despite in- 
creasing the production of hydroxyl radicals, exoge- 
nous nitric oxide does not appear to be detrimental 
to myocardial recovery after ischemia. Furthermore, 
we found a significant synergism between nitric 
oxide and aspirin in terms of improvement of coro- 
nary flow and myocardial recovery after ischemia/ 
reperfusion i jury. Aspirin appears to have acted in 
part as a scavenger of hydroxyl radicals. Moreover, 
aspirin, by inhibiting the endoperoxide (prostag- 
landin) pathway, reduces .Oe- production, de- 
creases the production of nitric oxide-derived hy- 
droxyl radicals, and prolongs the half-life of nitric 
oxide. This study provides a biochemical basis for 
the possible utility of two readily available agents in 
clinical myocardial protection strategies. 
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